HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hagop M Kantarjian Selected Research

ruxolitinib

10/2020Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era.
1/2020A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia.
1/2019A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis.
10/2018A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis.
10/2018Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation.
1/2018Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.
1/2018A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.
10/2017Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.
1/2017Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.
9/2015A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hagop M Kantarjian Research Topics

Disease

160Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
02/2024 - 06/2002
142BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
05/2024 - 03/2002
104Neoplasms (Cancer)
03/2024 - 07/2002
94Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
05/2024 - 01/2002
85Philadelphia Chromosome
05/2024 - 04/2002
78Myelodysplastic Syndromes (Myelodysplastic Syndrome)
03/2024 - 05/2002
75Leukemia
05/2024 - 02/2002
33Primary Myelofibrosis (Myelosclerosis)
04/2024 - 04/2003
26Hematologic Neoplasms (Hematological Malignancy)
01/2020 - 01/2002
21Blast Crisis (Blast Phase)
01/2024 - 05/2002
20Residual Neoplasm
05/2024 - 01/2003
20B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
01/2022 - 04/2003
19Thrombocytopenia (Thrombopenia)
01/2023 - 09/2002
16Neutropenia
01/2024 - 06/2003
15Disease Progression
05/2024 - 03/2002
15Anemia
04/2024 - 04/2002
13Acute Promyelocytic Leukemia
12/2023 - 06/2002
13Infections
01/2023 - 01/2002
12Myeloid Leukemia (Leukemia, Myelocytic)
01/2020 - 06/2002
11Fibrosis (Cirrhosis)
01/2022 - 07/2005
11Exanthema (Rash)
01/2021 - 03/2003
11Diarrhea
01/2019 - 08/2002
11Splenomegaly
01/2019 - 10/2004
10Chromosome Aberrations (Chromosome Abnormalities)
01/2023 - 04/2004
9Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic)
03/2024 - 04/2003
9Lymphoma (Lymphomas)
01/2019 - 12/2003
8Fatigue
01/2021 - 04/2003
8Polycythemia Vera
01/2017 - 06/2006
7Febrile Neutropenia
11/2021 - 07/2012
7Pleural Effusion (Pleural Effusions)
01/2020 - 06/2005
6Hairy Cell Leukemia
05/2024 - 12/2003
6Pneumonia (Pneumonitis)
01/2022 - 09/2007
6Cytopenia
01/2021 - 05/2006
6Pathologic Complete Response
01/2019 - 06/2002
5Edema (Dropsy)
01/2019 - 08/2002
5Fever (Fevers)
01/2018 - 06/2005
5Essential Thrombocythemia
10/2017 - 06/2006
5Myeloproliferative Disorders (Myeloproliferative Disorder)
06/2006 - 04/2003

Drug/Important Bio-Agent (IBA)

91Imatinib Mesylate (Gleevec)FDA Link
05/2024 - 03/2002
75Tyrosine Kinase InhibitorsIBA
05/2024 - 09/2003
50Cytarabine (Cytosar-U)FDA LinkGeneric
01/2024 - 04/2002
35DecitabineFDA Link
12/2021 - 08/2003
34venetoclaxIBA
01/2024 - 12/2015
33Proteins (Proteins, Gene)FDA Link
01/2023 - 06/2002
33Dasatinib (BMS 354825)FDA Link
05/2022 - 02/2007
27nilotinibFDA Link
07/2021 - 02/2007
26Azacitidine (5 Azacytidine)FDA Link
01/2023 - 05/2002
22ruxolitinibIBA
10/2020 - 01/2009
21Inotuzumab OzogamicinIBA
03/2024 - 08/2016
19Phosphotransferases (Kinase)IBA
01/2019 - 11/2005
18blinatumomabIBA
06/2023 - 03/2014
15Rituximab (Mabthera)FDA Link
05/2024 - 04/2003
15Clofarabine (Clolar)FDA Link
02/2017 - 03/2003
14bosutinibIBA
01/2024 - 05/2011
13ponatinibIBA
05/2024 - 06/2013
13Cyclophosphamide (Cytoxan)FDA LinkGeneric
01/2021 - 01/2002
13Vincristine (Oncovin)FDA LinkGeneric
01/2021 - 01/2002
13bcr-abl Fusion ProteinsIBA
01/2020 - 03/2002
12Monoclonal AntibodiesIBA
11/2023 - 04/2003
12NucleosidesIBA
01/2023 - 02/2002
12fludarabineIBA
01/2022 - 04/2002
12Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric
08/2021 - 06/2002
12Dexamethasone (Maxidex)FDA LinkGeneric
01/2021 - 01/2002
10DNA (Deoxyribonucleic Acid)IBA
01/2019 - 06/2002
9Interferon-alpha (Interferon Alfa)IBA
02/2008 - 04/2002
8enasidenibIBA
01/2023 - 10/2017
8Reticulin (Reticular Fiber)IBA
01/2022 - 07/2005
8Lenalidomide (CC 5013)FDA Link
01/2021 - 08/2006
8Doxorubicin (Adriamycin)FDA LinkGeneric
01/2021 - 01/2002
8CytokinesIBA
01/2020 - 07/2003
7Arsenic Trioxide (Trisenox)FDA Link
12/2023 - 09/2004
7Hemoglobins (Hemoglobin)IBA
11/2023 - 04/2002
7MethyltransferasesIBA
01/2023 - 08/2007
7Gemtuzumab (Mylotarg)FDA Link
01/2022 - 06/2002
7Methotrexate (Mexate)FDA LinkGeneric
01/2018 - 04/2003
6CladribineFDA LinkGeneric
05/2024 - 06/2006
6Tretinoin (Retinoic Acid)FDA LinkGeneric
01/2022 - 06/2002
6Core Binding Factors (Core-Binding Factor)IBA
01/2022 - 05/2009
6Granulocyte Colony-Stimulating Factor (G-CSF)IBA
10/2021 - 01/2002
6Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
01/2020 - 05/2002
6Transaminases (Aminotransferases)IBA
01/2020 - 01/2008
6Janus Kinase 2IBA
01/2019 - 11/2005
6Janus Kinase InhibitorsIBA
02/2014 - 01/2013
6troxacitabineIBA
01/2007 - 02/2002
5ivosidenibIBA
02/2024 - 01/2020
5Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA
01/2023 - 10/2017
5EnzymesIBA
01/2023 - 11/2002
5fms-Like Tyrosine Kinase 3IBA
01/2022 - 10/2012
5NucleophosminIBA
01/2021 - 10/2009
5Histone Deacetylase InhibitorsIBA
12/2017 - 11/2006
5InterferonsIBA
01/2017 - 06/2003
5HomoharringtonineIBA
01/2016 - 04/2002
5Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
06/2004 - 11/2002

Therapy/Procedure

223Therapeutics
03/2024 - 04/2002
63Drug Therapy (Chemotherapy)
03/2024 - 01/2002
14Salvage Therapy
01/2021 - 10/2008
12Stem Cell Transplantation
12/2019 - 09/2002
10Induction Chemotherapy
01/2022 - 01/2002
9Drug Tapering
01/2020 - 06/2003
8Aftercare (After-Treatment)
01/2023 - 08/2002